Arvinas, Inc. (ARVN) stock
ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.82+0.05 (+0.74%)
Close on Nov 17, 2026Market cap $445.93MP/E 42.6Yield –
Arvinas cash
Cash and short-term investments held at the end of each period.
Arvinas's cash was $567.90M at Jun 30, 2026. For fiscal 2025 it was $685.40M, down 34.1% from the year before. The highest annual figure on record is $1.51B in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $685.40M | -34.1% |
| FY2024 | Dec 31, 2024 | $1.04B | -17.6% |
| FY2023 | Dec 31, 2023 | $1.26B | +4.1% |
| FY2022 | Dec 31, 2022 | $1.21B | -19.7% |
| FY2021 | Dec 31, 2021 | $1.51B | +118.9% |
| FY2020 | Dec 31, 2020 | $688.60M | +145.2% |
| FY2019 | Dec 31, 2019 | $280.86M | +49.5% |
| FY2018 | Dec 31, 2018 | $187.84M | +379.5% |
| FY2017 | Dec 31, 2017 | $39.17M | +669.8% |
| FY2016 | Dec 31, 2016 | $5.09M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $567.90M | -34.1% |
| Q1 FY2026 | Mar 31, 2026 | $614.90M | -35.6% |
| Q4 FY2025 | Dec 31, 2025 | $685.40M | -34.1% |
| Q3 FY2025 | Sep 30, 2025 | $787.60M | -29.8% |
| Q2 FY2025 | Jun 30, 2025 | $861.20M | -29.9% |
| Q1 FY2025 | Mar 31, 2025 | $954.30M | -18.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.04B | -17.6% |
| Q3 FY2024 | Sep 30, 2024 | $1.12B | +12.3% |
| Q2 FY2024 | Jun 30, 2024 | $1.23B | +18.3% |
| Q1 FY2024 | Mar 31, 2024 | $1.17B | +4.1% |
| Q4 FY2023 | Dec 31, 2023 | $1.26B | +4.1% |
| Q3 FY2023 | Sep 30, 2023 | $998.50M | -21.4% |
| Q2 FY2023 | Jun 30, 2023 | $1.04B | -22.7% |
| Q1 FY2023 | Mar 31, 2023 | $1.12B | -21.3% |
| Q4 FY2022 | Dec 31, 2022 | $1.21B | -19.7% |
| Q3 FY2022 | Sep 30, 2022 | $1.27B | -18.0% |
| Q2 FY2022 | Jun 30, 2022 | $1.34B | +122.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.43B | +119.3% |
| Q4 FY2021 | Dec 31, 2021 | $1.51B | +118.9% |
| Q3 FY2021 | Sep 30, 2021 | $1.55B | +523.2% |
| Q2 FY2021 | Jun 30, 2021 | $605.05M | +149.3% |
| Q1 FY2021 | Mar 31, 2021 | $651.30M | +147.8% |
| Q4 FY2020 | Dec 31, 2020 | $688.60M | +145.2% |
| Q3 FY2020 | Sep 30, 2020 | $248.56M | +30.5% |
| Q2 FY2020 | Jun 30, 2020 | $242.70M | +52.5% |
| Q1 FY2020 | Mar 31, 2020 | $262.83M | +50.2% |
| Q4 FY2019 | Dec 31, 2019 | $280.86M | +49.5% |
| Q3 FY2019 | Sep 30, 2019 | $190.51M | +112.2% |
| Q2 FY2019 | Jun 30, 2019 | $159.17M | +4647.8% |
| Q1 FY2019 | Mar 31, 2019 | $174.96M | +187.6% |
| Q4 FY2018 | Dec 31, 2018 | $187.84M | +379.5% |
| Q3 FY2018 | Sep 30, 2018 | $89.79M | +3554.6% |
| Q2 FY2018 | Jun 30, 2018 | $3.35M | -34.1% |
| Q1 FY2018 | Mar 31, 2018 | $60.83M | – |
| Q4 FY2017 | Dec 31, 2017 | $39.17M | – |
| Q3 FY2017 | Sep 30, 2017 | $2.46M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.09M | – |
See a number that looks wrong?